Age (yr), median (25th–75th percentile) |
57 (49–66) |
Female, n (%) |
227 (30) |
Race, n (%) |
White |
445 (59) |
Black |
265 (35) |
Other |
48 (6) |
Resting systolic blood pressure (mmHg), median (25th–75th percentile) |
112 (102–128) |
Resting diastolic blood pressure (mmHg), median (25th–75th percentile) |
70 (62–80) |
Resting seated HR before exercise test (beats•min−1), median (25th–75th percentile) |
69 (61–77) |
Weight (kg), median (25th–75th percentile) |
91 (77–108) |
Body mass index (kg•m−2), median (25th–75th percentile) |
30 (26–36) |
Left ventricular ejection fraction (%), median (25th–75th percentile) |
25 (21–31) |
History of diabetes, n (%) |
251 (33) |
History of stroke, n (%) |
68 (9) |
History of hypertension, n (%) |
454 (60) |
Etiology of HF, ischemic, n (%) |
375 (49) |
New York Heart Association Functional Class, n (%) |
II |
557 (73) |
III/IV |
210 (27) |
Number of HF hospitalizations in previous 6 months, n (%) |
0 |
568 (74) |
1 |
152 (20) |
2+ |
42 (5) |
Peak exercise HR (beats•min−1), median (25th–75th percentile) |
125 (111–140) |
Peak oxygen uptake (mL•kg−1•min−1), median (25th–75th percentile) |
15.7 (12.5–19.0) |
Peak RER, median (25th–75th percentile) |
1.13 (1.09–1.19) |
Peak RPE (Borg, 6-20), median (25th–75th percentile) |
17 (15–19) |
Prior coronary artery bypass graft surgery, n (%) |
154 (20) |
Prior percutaneous coronary intervention, n (%) |
161 (21) |
Prior myocardiac infarction, n (%) |
318 (41) |
History of atrial fibrillation/flutter, n (%) |
71 (9) |
History of peripheral vascular occlusive disease, n (%) |
39 (5) |
History of depression, n (%) |
152 (20) |
Angiotension-coverting enzyme inhibitor, n (%) |
584 (76) |
Dose of β-adrenergic blocking agent, carvedilol equivalents (mg•d−1), median (25th–75th percentile) |
40 (25–50) |